Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial

Abstract Background Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurrent diabetes and CKD on the efficacy and safety of eplerenone in acute HF...

Full description

Bibliographic Details
Published in:	Cardiovascular Diabetology
Main Authors:	Masatake Kobayashi, Akira Yamashina, Kazuhiro Satomi, Masataka Watanabe, Ryu Takagi, Ayako Tezuka, Shin Ito, Masanori Asakura, Masafumi Kitakaze
Format:	Article
Language:	English
Published:	BMC 2025-03-01
Subjects:	Acute heart failure Eplerenone Mineralocorticoid receptor antagonist Diabetes Chronic kidney disease Prognosis
Online Access:	https://doi.org/10.1186/s12933-025-02659-y

Similar Items

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
by: Kapil G. Kapoor, et al.
Published: (2015-12-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis
by: Ahmed Elshahat, et al.
Published: (2024-09-01)

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial
by: Subha V. Raman, et al.
Published: (2017-02-01)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
by: Akira Sezai, et al.
Published: (2025-05-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
by: A. G. Evdokimova, et al.
Published: (2023-01-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Possible dose-dependent effect of eplerenone on intraocular pressure
by: Seyedeh Mehrsa Sadat Razavi, et al.
Published: (2023-01-01)

TRAITEMENT PAR ÉPLÉRÉNONE DANS LA CHORIORÉTINITE SÉREUSE CENTRALE CHRONIQUE : À PROPOS DE 8 CAS
by: A. El ouafi, et al.
Published: (2019-06-01)

Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome
by: O. A. Osipova, et al.
Published: (2022-07-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial
by: Niels H. Brandt-Jacobsen, et al.
Published: (2023-03-01)

Cardiac response to chronic restraint stress involves mineralocorticoid receptors in male Sprague–Dawley rats
by: D. Sztechman, et al.
Published: (2025-10-01)

A Prospective Study of Eplerenone in the Treatment of Patients with Glomerulonephritis
by: Marios Papasotiriou, et al.
Published: (2023-12-01)

EVIDENCE-BASED USE OF EPLERENONE
by: S. R. Gilyarevski, et al.
Published: (2014-07-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Dexamethasone-associated metabolic effects in male mice are partially caused by depletion of endogenous corticosterone
by: Lisa L. Koorneef, et al.
Published: (2022-08-01)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
by: Yu. M. Lopatin, et al.
Published: (2015-08-01)

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
by: Mario Boehm, et al.
Published: (2018-03-01)

Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats
by: Xue Wang, et al.
Published: (2020-08-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy
by: Wael Ahmed Ewais, et al.
Published: (2025-06-01)

New Clinical Aspects of Eplerenone Use in Clinical Practice
by: S. R. Gilyarevskiy, et al.
Published: (2018-09-01)

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
by: Jinfei Wu, et al.
Published: (2025-09-01)

Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone – a case report
by: Ramesh Venkatesh, et al.
Published: (2020-06-01)

Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy
by: Pramod Kumar Sharma, et al.
Published: (2025-01-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

Ocena skuteczności i bezpieczeństwa farmakoterapii inhibitorami aldosteronu w niewydolności serca = Evaluation of the efficacy and safety of pharmacotherapy using aldosterone antagonists in heart failure
by: Agata Tarczykowska, et al.
Published: (2015-07-01)

Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy
by: Lin Xie, et al.
Published: (2024-05-01)

Oral Eplerenone Versus Observation in the Management of Acute Central Serous Chorioretinopathy: A Prospective, Randomized Comparative Study
by: Ramesh Venkatesh, et al.
Published: (2020-07-01)

Real-world practice patterns of eplerenone use for central serous chorioretinopathy
by: Ramesh Venkatesh, et al.
Published: (2023-10-01)

Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy
by: Natalie K. Binder, et al.
Published: (2025-05-01)

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
by: A. Yu. Zharikov, et al.
Published: (2021-07-01)

Synthesis and Physicochemical Characterization of the Process-Related Impurities of Eplerenone, an Antihypertensive Drug
by: Iwona Dams, et al.
Published: (2017-08-01)

EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial
by: Sophie Girerd, et al.
Published: (2018-10-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

The effect of aldosterone receptor antagonists on cardiovascular system in maintenance hemodialysis patients
by: JIANG Mei, et al.
Published: (2020-01-01)

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure
by: C McKenna, et al.
Published: (2010-05-01)

Formulation and Characterization of Eplerenone Nanocrystal as Sublingual Fast-dissolving Film
by: Hawraa Kareem, et al.
Published: (2024-12-01)